Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03630159 |
| Title | Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (PORTIA) |
| Acronym | PORTIA |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | CAN | AUT |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Emory University School of Medicine SC CTL019 | Atlanta | Georgia | 30322 | United States | Details | |
| University of Chicago Medical Center Hematology and Oncology | Chicago | Illinois | 60637 | United States | Details | |
| University of Kansas Hospital and Medical Center U of Kansas Cancer Center | Kansas City | Kansas | 66160 | United States | Details | |
| Novartis Investigative Site | Wien | 1090 | Austria | Details | ||
| Novartis Investigative Site | Montreal | Quebec | H1T 2M4 | Canada | Details |